Navigation Links
Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures™ Educational Campaign
Date:8/25/2011

ractices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of Aug. 25, 2011 and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. DOE Labs Take Pride in Award-Winning IBM Blue Gene Series
2. Award-winning supercomputer application solves superconductor puzzle
3. Rice Universitys award-winning NanoJapan program wins $4M grant
4. Actress and Singer, Cynthia Basinet Petitions United Nations
5. Amgen Announces Webcast of 2008 Third Quarter Financial Results
6. Amgens Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
7. Call for Applications: The Amgen Award for Science Teaching Excellence
8. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
9. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
10. Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe
11. Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2014)... WI (PRWEB) November 23, 2014 ... and supplier of fine chemical ingredients to the ... the launch of its new website, Apiscent.com. , ... of Apiscent Labs, clean design, easy navigation, rotating ... make Apiscent Labs stand out. , ...
(Date:11/22/2014)... During his lifetime Richard L. Sharp was a ... with great people and take risks to achieve success. ... at his extraordinarily courageous attitude when taking on challenges. ... with his death impending—that’s how he continued looking for ... take his life. , Carrying on Sharp’s relentless dream ...
(Date:11/22/2014)... 21, 2014 CannLabs, Inc. ... analytics and scientific testing methodologies relating to cannabis, today ... $750,000 line of credit from an existing stockholder of ... have secured this commitment from one of our existing ... CannLabs. “This capital will help accelerate our planned expansions ...
(Date:11/22/2014)... On November 17th Chicago start-up Briteseed outperformed 137 ... Summit in San Francisco to take first place in ... Valley investors and technology elites as the premier showcase ... Briteseed to move on to the final phase ... with other elite innovation finalists for a $125,000 cash ...
Breaking Biology Technology:Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3CannLabs Secures $750,000 Line Of Credit 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3
... proxy, FOR the Election of, Two ... May 15 /PRNewswire/ - The Concerned Shareholders of Biovail ... (TSX:BVF) continues to mislead its shareholders by making the ... requisition was simply about governance reform and has already ...
... Nile Therapeutics, Inc. (Nasdaq: NLTX ... therapeutics for heart failure patients, received notification from the ... has released the Company,s CD-NP development program from clinical ... the FDA the finalized protocol for the Company,s planned ...
... Trials of Carfilzomib in Relapsed/Refractory Multiple Myeloma and Advanced ... 15 Proteolix, Inc. today announced that data from ... solid tumors will be presented at the 2009 Annual ... being held May 29 - June 2, 2009 in ...
Cached Biology Technology:The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 2The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 3The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 4The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 5The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 6The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 7Nile Therapeutics CD-NP Clinical Program for Acute Heart Failure Released From Clinical Hold by FDA 2Nile Therapeutics CD-NP Clinical Program for Acute Heart Failure Released From Clinical Hold by FDA 3Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting 2Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting 3
(Date:11/3/2014)... Research and Markets has announced the ... Markets and Companies" to their offering. ... which have already started to play an important role in ... the old fashioned bone marrow transplants. Role of cells in ... become a part of medical practice. Stem cells ...
(Date:11/3/2014)...  NeuroSigma ® , Inc. (NeuroSigma), a ... on commercialization of its non-invasive Monarch ... neurological and neuropsychiatric disorders, announced today that the ... Notice of Allowance for Mexican Patent Application No. ... and the Regents of the University of California ...
(Date:11/2/2014)... of Physics World , James Dacey explores the ... death" to take their innovations from the lab into ... challenge facing all start-up companies as they move from ... of two main factors: physics-based inventions are usually far ... out to be a lot more complicated than had ...
Breaking Biology News(10 mins):Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3The 'valley of death' facing physics start-ups 2
... Ariz. (Sept. 13, 2012) -- Shane Snyder, who earlier ... Water Works Association (AWWA), has been invited to present ... 3,500 at the 2012 International Water Association,s (IWA) World ... professor,s presentation will focus not only on his research ...
... Scientists have found the answer to why female killer whales have ... their adult sons. Led by the Universities of Exeter and York ... the research shows that, for a male over 30, the death ... his death within the following year. The reason for the ...
... of bioengineering at Stanford University, has won a Director,s ... award includes a five-year, $2.5 million grant to be ... to affect a broad area of biomedical or behavioral ... to explore the use of synthetic biology platforms and ...
Cached Biology News:UA engineering professor Shane Snyder to speak in Korea on international water quality 2Long menopause allows killer whales to care for adult sons 2Long menopause allows killer whales to care for adult sons 3
... Thermal Cycler (MBS) is a ... medium to high throughput PCR. ... latest in satellite block technology, ... control, resulting in a system ...
...
45° Fixed Angle Rotor for use in the IEC Centra CL2, Centra CL3/CL3R, HN-SII, and the Centra-MP4/MP4R....
CQCS kit for etra KR 4i , (other units)....
Biology Products: